Bausch Health Companies Inc. Write off of Deferred Debt Issuance Cost
Bausch Health Companies Inc. (BHC) reported Write off of Deferred Debt Issuance Cost of $8.20 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2013-02-28
- Bausch Health Companies Inc. write off of deferred debt issuance cost for the quarter ending 2010-12-31 was $0.00.
- Bausch Health Companies Inc. write off of deferred debt issuance cost for the quarter ending 2010-09-30 was $5.77M.
- Bausch Health Companies Inc. write off of deferred debt issuance cost for the quarter ending 2009-12-31 was $0.00.
- Bausch Health Companies Inc. write off of deferred debt issuance cost for fiscal 2012 was $8.20M, a 452.19% increase from fiscal 2011.
- Bausch Health Companies Inc. write off of deferred debt issuance cost for fiscal 2011 was $1.49M, a 74.28% decline from fiscal 2010.
- Bausch Health Companies Inc. write off of deferred debt issuance cost for fiscal 2010 was $5.77M, a 975.23% increase from fiscal 2009.
- Bausch Health Companies Inc. write off of deferred debt issuance cost for fiscal 2009 was $537.00K.
| Period end | Write off of Deferred Debt Issuance Cost 3 month | Write off of Deferred Debt Issuance Cost 6 month | Write off of Deferred Debt Issuance Cost 9 month | Write off of Deferred Debt Issuance Cost 12 month |
|---|---|---|---|---|
| 2012-12-31 | $8.20M 10-K · filed 2013-02-28 | |||
| 2011-12-31 | $1.49M 10-K · filed 2013-02-28 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $5.77M derived: sum of 2 quarters · filed 2013-02-28 | $5.77M 10-K · filed 2013-02-28 | |
| 2010-09-30 | $5.77M 10-Q · filed 2011-11-04 | $5.77M 10-Q · filed 2011-11-04 | ||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $537.00K 10-K · filed 2012-02-29 | ||
| 2009-09-30 | $537.00K 10-Q · filed 2010-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |